{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T01:29:29Z","timestamp":1768699769886,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007951","name":"Tokyo Medical and Dental University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19cm0106365h0001"],"award-info":[{"award-number":["19cm0106365h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21cm0106386h0001"],"award-info":[{"award-number":["21cm0106386h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K07512"],"award-info":[{"award-number":["JP20K07512"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bbrc.2021.08.051","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T10:21:00Z","timestamp":1629541260000},"page":"104-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells"],"prefix":"10.1016","volume":"574","author":[{"given":"Nobuyo","family":"Kondo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2974-990X","authenticated-orcid":false,"given":"Atsuhiko","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miku","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniko","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeru","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3433-2658","authenticated-orcid":false,"given":"Mari","family":"Kannagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2021.08.051_bib1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.bbrc.2021.08.051_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00277-006-0217-y","article-title":"Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses","volume":"86","author":"Giagounidis","year":"2007","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bbrc.2021.08.051_bib3","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2014-11-567792","article-title":"Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities","volume":"125","author":"Kritharis","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2021.08.051_bib4","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.bbrc.2021.08.051_bib5","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00109-016-1450-z","article-title":"The molecular mechanism of thalidomide analogs in hematologic malignancies","volume":"94","author":"Lindner","year":"2016","journal-title":"J.\u00a0Mol. Med. (Berl.)"},{"key":"10.1016\/j.bbrc.2021.08.051_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2021.08.051_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2021.08.051_bib8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2021.08.051_bib9","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Canc. J."},{"key":"10.1016\/j.bbrc.2021.08.051_bib10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbrc.2015.11.116","article-title":"Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells","volume":"469","author":"Endo","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2021.08.051_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12977-020-00535-z","article-title":"Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma","volume":"17","author":"Rauch","year":"2020","journal-title":"Retrovirology"},{"key":"10.1016\/j.bbrc.2021.08.051_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1546544","article-title":"Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells","volume":"8","author":"Davis","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.bbrc.2021.08.051_bib13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","article-title":"Adult T-cell leukemia: clinical and hematologic features of 16 cases","volume":"50","author":"Uchiyama","year":"1977","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2021.08.051_bib14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(85)92734-5","article-title":"Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis","volume":"2","author":"Gessain","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2021.08.051_bib15","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(86)91298-5","article-title":"HTLV-I associated myelopathy, a new clinical entity","volume":"1","author":"Osame","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2021.08.051_bib16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev.immunol.19.1.475","article-title":"Multiple viral strategies of HTLV-1 for dysregulation of cell growth control","volume":"19","author":"Yoshida","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2021.08.051_bib17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12977-020-0511-0","article-title":"HTLV-1 bZIP factor: the key viral gene for pathogenesis","volume":"17","author":"Matsuoka","year":"2020","journal-title":"Retrovirology"},{"key":"10.1016\/j.bbrc.2021.08.051_bib18","first-page":"2360","article-title":"Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells","volume":"93","author":"Mori","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2021.08.051_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1385\/IR:34:1:1","article-title":"Modulation of nuclear factor-kappaB by human T cell leukemia virus type 1 Tax protein: implications for oncogenesis and inflammation","volume":"34","author":"Peloponese","year":"2006","journal-title":"Immunol. Res."},{"key":"10.1016\/j.bbrc.2021.08.051_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/156652410791316968","article-title":"Molecular pathways linking inflammation and cancer","volume":"10","author":"Mantovani","year":"2010","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.bbrc.2021.08.051_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1126\/science.7604283","article-title":"Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I","volume":"269","author":"Migone","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2021.08.051_bib22","doi-asserted-by":"crossref","first-page":"13897","DOI":"10.1073\/pnas.94.25.13897","article-title":"Proliferation of adult T cell leukemia\/lymphoma cells is associated with the constitutive activation of JAK\/STAT proteins","volume":"94","author":"Takemoto","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2021.08.051_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006597","article-title":"IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways","volume":"13","author":"Sawada","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bbrc.2021.08.051_bib24","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.biopha.2017.12.059","article-title":"Double sword role of EZH2 in leukemia","volume":"98","author":"Safaei","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2021.08.051_bib25","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","article-title":"Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma","volume":"77","author":"Poiesz","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2021.08.051_bib26","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/294770a0","article-title":"Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells","volume":"294","author":"Miyoshi","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2021.08.051_bib27","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1084\/jem.162.6.2169","article-title":"Origin of human T-lymphotrophic virus I-positive T cell lines in adult T cell leukemia. Analysis of T cell receptor gene rearrangement","volume":"162","author":"Maeda","year":"1985","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.bbrc.2021.08.051_bib28","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1080\/1042819031000099652","article-title":"Effects of all-trans retinoic acid (ATRA) on human myeloma cells","volume":"44","author":"Otsuki","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbrc.2021.08.051_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1620\/tjem.157.1","article-title":"Monoclonal antibody defining tax protein of human T-cell leukemia virus type-I","volume":"157","author":"Lee","year":"1989","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.bbrc.2021.08.051_bib30","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1084\/jem.20171417","article-title":"Macrophage\/microglial Ezh2 facilitates autoimmune inflammation through inhibition of Socs3","volume":"215","author":"Zhang","year":"2018","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.bbrc.2021.08.051_bib31","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1076997","article-title":"Role of histone H3 lysine 27 methylation in Polycomb-group silencing","volume":"298","author":"Cao","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2021.08.051_bib32","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1021\/ml3003346","article-title":"Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2","volume":"3","author":"Verma","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbrc.2021.08.051_bib33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4143\/crt.2014.46.3.209","article-title":"Regulation and role of EZH2 in cancer","volume":"46","author":"Yamaguchi","year":"2014","journal-title":"Canc. Res. Treat."},{"key":"10.1016\/j.bbrc.2021.08.051_bib34","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3324\/haematol.2010.028605","article-title":"Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia\/lymphoma as a target for epigenetic therapy","volume":"96","author":"Sasaki","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bbrc.2021.08.051_bib35","doi-asserted-by":"crossref","first-page":"669","DOI":"10.18632\/oncotarget.327","article-title":"Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms","volume":"2","author":"Koh","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2021.08.051_bib36","doi-asserted-by":"crossref","first-page":"9211","DOI":"10.1158\/0008-5472.CAN-09-1622","article-title":"EZH2 is essential for glioblastoma cancer stem cell maintenance","volume":"69","author":"Suva","year":"2009","journal-title":"Canc. Res."},{"key":"10.1016\/j.bbrc.2021.08.051_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052984","article-title":"EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer","volume":"7","author":"Cao","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2021.08.051_bib38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-016-0561-z","article-title":"STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer","volume":"15","author":"Pan","year":"2016","journal-title":"Mol. Canc."},{"key":"10.1016\/j.bbrc.2021.08.051_bib39","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","article-title":"Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells","volume":"23","author":"Kim","year":"2013","journal-title":"Canc. Cell"},{"key":"10.1016\/j.bbrc.2021.08.051_bib40","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2021.08.051_bib41","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood-2015-08-662593","article-title":"Polycomb-dependent epigenetic landscape in adult T-cell leukemia","volume":"127","author":"Fujikawa","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2021.08.051_bib42","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.1073\/pnas.1502166113","article-title":"Epigenetic regulation of Kcna3-encoding Kv1.3 potassium channel by cereblon contributes to regulation of CD4+ T-cell activation","volume":"113","author":"Kang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2021.08.051_bib43","doi-asserted-by":"crossref","first-page":"8823","DOI":"10.1038\/ncomms9823","article-title":"Ikaros mediates gene silencing in T cells through Polycomb repressive complex 2","volume":"6","author":"Oravecz","year":"2015","journal-title":"Nat. Commun."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21012286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21012286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:10:46Z","timestamp":1757765446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X21012286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":43,"alternative-id":["S0006291X21012286"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.08.051","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.08.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}